Molecular and laboratory techniques

The evolution of molecular biology began with the ability to visualise DNA fragments on membranes, a method known as Southern blotting. This laid the groundwork for later technologies that could not only detect but also amplify and edit genetic material. Modern medical curricula expect students to understand the principles, applications and limitations of three cornerstone techniques: the Polymerase Chain Reaction (PCR), CRISPR‑Cas9 genome editing, and Southern blot analysis.

Polymerase Chain Reaction revolutionised genetics by enabling exponential amplification of a defined DNA segment from minute starting material. The reaction relies on three temperature‑controlled steps repeated over 20–40 cycles:

• Denaturation – heating to separate the double‑stranded template.
• Annealing – cooling to allow short oligonucleotide primers to bind flanking the target region.
• Extension – a thermostable DNA polymerase synthesises a new strand from the primer’s 3’ end.

Because each cycle doubles the amount of target DNA, the final product can be large numbers of copies of the original fragment, sufficient for downstream applications such as sequencing by laser‑induced fluorescence measurement and capillary gel electrophoresis【P7】. The speed and sensitivity of PCR dramatically reduced the time required for genotyping, permitting simultaneous analysis of variants and paving the way for high‑throughput platforms such as DNA microarrays【P7】. ^[1]

• Template quality – intact genomic DNA yields the most reliable amplification; degraded samples may produce truncated products.
• Primer design – specificity is achieved by selecting primers of appropriate length with a suitable melting temperature (Tm) and minimal secondary structure. ^[4]
• Cycling parameters – optimisation of denaturation (94–98 °C, 20–30 s), annealing (Tm ± 5 °C, 20–30 s) and extension (72 °C, 30 s per kb) maximises yield and fidelity.

• Contamination with extraneous DNA can generate false‑positive results; rigorous laboratory practices (separate pre‑ and post‑PCR areas, aerosol‑resistant tips) are essential.
• PCR inhibitors present in blood or tissue extracts (e.g., heme, polysaccharides) may reduce efficiency, a concern less critical for Southern blotting where DNA integrity is the primary pre‑analytical factor【P349】.

CRISPR‑Cas9 is a programmable nuclease system derived from bacterial adaptive immunity. A synthetic single‑guide RNA (sgRNA) directs the Cas9 endonuclease to a complementary 20‑base genomic sequence adjacent to a protospacer‑adjacent motif (PAM). Binding triggers a double‑strand break, which cellular repair pathways resolve by non‑homologous end joining (introducing insertions/deletions) or homology‑directed repair (allowing precise sequence insertion when a donor template is supplied.

• Cas9 protein – the molecular scissors that cleave DNA.
• sgRNA – a chimeric RNA combining a CRISPR RNA (crRNA) that defines target specificity and a trans‑activating crRNA (tracrRNA) that binds Cas9.
• PAM (NGG for Streptococcus pyogenes Cas9) – a short motif required for Cas9 activity; its presence restricts targetable sites.

1. Design sgRNA complementary to the exon of interest.
2. Clone sgRNA into an expression vector or synthesise as RNA.
3. Co‑deliver Cas9 and sgRNA into cultured cells (electroporation, lipid transfection, or viral vectors).
4. Screen clones by PCR and sequencing to confirm indel formation.

• Generation of disease models (e.g., patient‑derived iPSC lines).
• Potential therapeutic correction of pathogenic mutations (currently in early‑phase clinical trials).
• Functional genomics screens to identify drug targets.

• Off‑target cleavage can occur at sites with partial homology, necessitating careful sgRNA design and validation.
• Delivery efficiency varies between cell types; viral vectors raise immunogenicity concerns.

Southern blotting remains the reference method for measuring terminal restriction fragment (TRF) length, a proxy for telomere length, and for confirming the presence, size and copy number of specific DNA fragments. The technique involves:

1. Restriction digestion of genomic DNA with enzymes that cut at known sites, generating fragments of varying lengths.
2. Gel electrophoresis to separate fragments by size.
3. Transfer of DNA from the gel onto a nylon or nitrocellulose membrane by capillary action.
4. Hybridisation with a labelled probe complementary to the region of interest.
5. Detection of the probe‑DNA complex, producing a visual band pattern.

The Southern blot measures the mean TRF length and captures both canonical telomeric repeats and adjacent subtelomeric sequences, providing a comprehensive view of telomere architecture【P331】. In a comparative study of donor samples, Southern blotting demonstrated a low inter‑assay coefficient of variation (CV), markedly lower than that observed for quantitative PCR (qPCR) of telomere DNA content【P329】. Correlation coefficients (r) were high for repeat measurements, underscoring the method’s reproducibility【P329】. ^[4]

• High precision – low inter‑assay CV (1.74 %) and strong reproducibility (r > 0.9)【P329】. ^[4]
• Integrity‑dependent – requires high‑molecular‑weight DNA, ensuring that only intact genomes are analysed【P349】.
• Broad dynamic range – can resolve telomere lengths from a few kilobases to > 30 kb.

• Labor‑intensive – multiple steps (digestion, electrophoresis, transfer, hybridisation) extend turnaround time.
• Sample demand – several micrograms of high‑quality DNA are needed, limiting use with scarce clinical specimens.
• Resolution limits – cannot distinguish very short telomeres (< 1 kb) due to overlapping restriction fragments.

When a patient presents with a suspected telomere biology disorder, the laboratory may first perform qPCR for rapid screening. If results are abnormal or equivocal, a confirmatory Southern blot is ordered to obtain an accurate TRF measurement, guiding diagnosis and family counselling【P116】.

Northern and Western blotting are cornerstone techniques for detecting specific nucleic acids and proteins, respectively. Both rely on electrophoretic separation, transfer to a membrane, and hybridisation or antibody detection.

The workflow is similar for the two assays:

1. Sample preparation – RNA is extracted under RNase‑free conditions for Northern blots; proteins are lysed in SDS‑containing buffer for Western blots.
2. Electrophoresis – Denaturing agarose gels (Northern) or polyacrylamide gels (Western) resolve molecules by length or molecular weight.
3. Transfer – Capillary or electro‑blotting moves the nucleic acids or proteins onto a nitrocellulose or nylon membrane.
4. Fixation and blocking – Membranes are baked or UV‑crosslinked (Northern) or blocked with protein‑containing solution (Western) to prevent non‑specific binding.
5. Detection –
   • Northern: a digoxigenin (DIG)‑labelled probe is hybridised to the membrane. In a published protocol the membrane was hybridised at 65 °C with a DIG‑labelled telomeric probe overnight in 5× SSC, 0.1 % Sarkosyl, 0.02 % SDS and 1 % blocking reagent, then washed three times at room temperature in 2× SSC, 0.1 % SDS for 15 min each and once in 2× SSC for 15 min before detection with a luminescent substrate【P344】. ^[4]
   • Western: a primary antibody specific for the protein of interest binds, followed by a horseradish peroxidase‑conjugated secondary antibody; chemiluminescent substrates generate a signal captured on film or a digital imager.

Quantitative assessment can be performed by densitometry. In a telomere‑length study, the inter‑assay coefficient of variation (CV) for Southern blots (the DNA‑based analogue of Western blots) was low, compared with qPCR, illustrating the high reproducibility of blot‑based measurements【P351】. ^[4]

When applied to pharmacogenetics, blots can reveal inducible enzyme activity. For the CYP1A2 gene, more than half of the patients showed inducibility of enzymatic activity with both techniques, although mass‑spectrometry identified additional variants, highlighting the complementary nature of blotting and other molecular platforms【P36】. ^[1]

Tip: Use internal loading controls (e.g., GAPDH for Western, 18S rRNA for Northern) to normalise signal intensity across lanes.

Flow cytometry (FCM) analyses physical and fluorescent characteristics of individual cells in suspension, enabling rapid multiparametric profiling of heterogeneous populations. ^[2]

Modern instruments can assess up to 20 different characteristics per cell, and emerging mass‑spectrometry‑based cytometers promise to expand this capability dramatically【P126】. ^[2]

1. Sample staining – Fluorochrome‑conjugated antibodies bind surface or intracellular antigens.
2. Instrument setup – Voltage and compensation are adjusted to resolve each fluorochrome.
3. Acquisition – Cells pass through a laser beam; forward scatter (FSC) reflects size, side scatter (SSC) reflects granularity, and emitted fluorescence is captured in dedicated detectors.

Historically, data interpretation relied on subjective manual gating, where an analyst draws boundaries on two‑dimensional plots to define populations. This approach introduces variability; a recent review highlighted that manual gating can produce wide variation across analysts, underscoring the need for objective, automated pipelines【P195】.

The Flow Cytometry: Critical Assessment of Population Identification Methods (FlowCAP) challenges compared computational algorithms for two tasks: (i) reproducing expert manual gating of mammalian cell populations, and (ii) classifying samples based on external variables such as clinical outcome【P122】. Results demonstrated that several algorithms can match expert performance, paving the way for reproducible, high‑throughput analyses. ^[2]

• Compensation – Overlap between fluorochrome emission spectra must be mathematically corrected.
• Viability dyes – Exclude dead cells that can bind antibodies non‑specifically.
• Controls – Include unstained, single‑stained, and fluorescence‑minus‑one (FMO) controls to set gates accurately.

1. Stain peripheral blood mononuclear cells with CD3‑FITC, CD4‑PE, CD8‑APC, and a live/dead dye.
2. Acquire 100 000 events on a cytometer capable of 20‑parameter detection.
3. Apply an automated clustering algorithm (e.g., FlowSOM) to identify CD4⁺ and CD8⁺ T‑cell subsets without manual gates.
4. Export frequencies for downstream statistical analysis.

Both microarrays and enzyme‑linked immunosorbent assays (ELISA) translate molecular interactions into measurable signals, but they differ in scale and format.

Microarrays consist of thousands of immobilised DNA, RNA or protein probes on a solid surface. Hybridisation of labelled target nucleic acids generates a spatial fluorescence pattern that is scanned and quantified.

During the study referenced in the pharmacogenetics literature, microarrays were commercially discontinued part‑way through the investigation, limiting their availability for further validation【P41】. This exemplifies a practical limitation: reliance on proprietary platforms can jeopardise long‑term reproducibility when manufacturers withdraw products. ^[1]

ELISA detects soluble antigens or antibodies using a plate‑bound capture antibody, a detection antibody, and an enzymatic colour‑developing reaction. The assay is highly adaptable, allowing quantitative measurement of cytokines, hormones, or drug‑specific antibodies in serum or plasma.

Key steps include:

1. Coating – Plate wells are coated with capture antibody or antigen.
2. Blocking – Non‑specific binding sites are blocked with protein solution.
3. Sample incubation – Patient sample is added; target binds to the capture reagent.
4. Detection – A secondary antibody conjugated to horseradish peroxidase (HRP) binds the target.
5. Substrate addition – HRP converts a chromogenic substrate (e.g., TMB) to a coloured product; absorbance is read on a plate reader.

ELISA’s strengths are its simplicity, scalability to 96‑ or 384‑well formats, and quantitative output. Limitations include dependence on high‑quality antibodies and potential cross‑reactivity, which can be mitigated by rigorous validation.

• Screening – Microarrays can profile gene expression signatures that suggest disease subtypes, guiding further targeted testing.
• Monitoring – ELISA quantifies biomarkers (e.g., cytokines) to track treatment response or disease activity.

Both platforms complement blotting and flow cytometry: blots provide size‑specific validation, flow cytometry offers single‑cell resolution, microarrays deliver broad discovery, and ELISA supplies rapid quantitative read‑outs for routine clinical use.

Karyotyping begins with arresting cultured cells in metaphase, usually by adding a mitotic inhibitor such as colcemid. The cells are then swollen in a hypotonic solution, fixed, and dropped onto glass slides. After staining—commonly with Giemsa after trypsin digestion (G‑banding)—the characteristic light and dark bands become visible, each representing regions of differing AT/GC content. By arranging the chromosomes in a standard order (by size, centromere position and banding pattern) a karyotype is produced, which can reveal trisomies, monosomies, translocations, inversions and large deletions.

Fluorescence in situ hybridisation (FISH) builds on the same metaphase or interphase preparations but replaces the dye‑based banding with fluorescently labelled DNA probes that hybridise to specific genomic loci. The probes can be single‑copy (targeting a gene) or repeat‑rich (targeting telomeres, centromeres). After hybridisation and washing, the slides are examined under a fluorescence microscope; each probe emits a distinct colour, producing FISH signals that can be counted and localised. In practice, at least ten metaphases or interphase nuclei are examined to ensure reliable interpretation of signal number and distribution. ^[5]

Both techniques have complementary strengths. Conventional G‑banding provides a global view of the chromosome complement, useful for detecting large‑scale rearrangements, while FISH offers locus‑specific resolution, enabling detection of sub‑microscopic deletions, duplications or gene fusions that are invisible on a standard karyotype. Modern multiplex FISH (M‑FISH) uses a cocktail of differently coloured probes to paint each chromosome in a unique hue, facilitating rapid identification of complex rearrangements in a single assay. Researchers performed G‑banding, karyotyping

1. Cell culture and harvest – grow peripheral blood lymphocytes or fibroblasts, add colcemid, harvest cells.
2. Slide preparation – hypotonic swelling, fixation, dropping onto slides.
3. G‑banding – trypsin digestion, Giemsa staining, visual inspection of banding patterns.
4. Probe design for FISH – select bacterial‑BAC or synthetic oligonucleotide probes, label with fluorophores.
5. Hybridisation – denature DNA on slide, apply probe mix, incubate, wash.
6. Imaging – fluorescence microscopy, capture images, count signals in ≥10 metaphases or interphase nuclei.
7. Interpretation – compare signal number and location to reference controls; integrate with G‑banding findings.

Molecular cloning remains a cornerstone of modern biology, enabling the production of recombinant proteins, the generation of transgenic models and the functional analysis of genes. The workflow can be divided into four conceptual stages:

1. Fragment acquisition – DNA can be obtained by PCR amplification, restriction digestion of genomic DNA, or synthesis of oligonucleotides.
2. Vector preparation – a plasmid, viral genome or bacterial artificial chromosome is linearised with compatible restriction enzymes or prepared by Gibson assembly for seamless joining.
3. Ligation or recombination – the DNA fragment and vector are joined either by DNA ligase (traditional cloning) or by homology‑directed recombination (e.g., Gibson, In‑Fusion).
4. Transformation and selection – competent bacteria (commonly E. coli) are made to take up the recombinant plasmid; antibiotic resistance or colourimetric markers allow identification of successful clones.

• Restriction sites: Choose enzymes that generate compatible ends and do not cut within the insert.
• Reading frame: When cloning for protein expression, ensure the insert is in‑frame with any tags or fusion partners.
• Promoter choice: Bacterial expression uses strong promoters such as T7; eukaryotic expression may require CMV or tissue‑specific promoters.
• Copy number: High‑copy plasmids yield more DNA but can be toxic for large inserts; low‑copy vectors are preferable for unstable sequences.

1. PCR amplify the coding sequence of human EGFP with primers adding EcoRI and XhoI sites.
2. Digest the PCR product and the pET‑21a expression vector with the same enzymes.
3. Ligate the insert into the vector using T4 DNA ligase.
4. Transform E. coli DH5α, plate on ampicillin, and screen colonies by colony PCR.
5. Sequence positive clones to confirm fidelity, then transform an expression strain (e.g., BL21(DE3)) for protein production.

RNAi operates through the processing of dsRNA into short interfering RNAs (siRNAs) by the RNase III enzyme Dicer. The siRNAs are incorporated into the RNA‑induced silencing complex (RISC), guiding the complex to complementary mRNA molecules, which are then cleaved and degraded. This mechanism can be harnessed experimentally to knock down gene expression in a wide range of eukaryotic cells.

The phenomenon was described following the discovery that dsRNA can silence homologous genes, establishing RNAi as a universal gene‑regulatory system in eukaryotes. Since then, RNAi has been divided into two overlapping pathways: the RNAi pathway, triggered by exogenous or endogenous dsRNA, and the micro‑RNA (miRNA) pathway, which originates from hairpin‑structured primary transcripts. ^[3]

In some organisms, such as Caenorhabditis elegans, the silencing signal can spread throughout the body, a phenomenon termed systemic RNAi. Certain insects (e.g., Tribolium) also display a robust systemic response, allowing simple injection of dsRNA into larvae or pupae to achieve whole‑organism knock‑down. By contrast, the model insect Drosophila lacks a strong systemic RNAi response, necessitating alternative delivery methods (e.g., transgenic expression of hairpin RNAs) to study the pathway. ^[3]

1. Design of dsRNA/siRNA – Choose a 21‑23 nt sequence unique to the target gene, avoiding off‑target homology.
2. Synthesis – In vitro transcription from a DNA template (T7 promoter) yields long dsRNA; commercial kits can generate siRNA duplexes.
3. Delivery –
   • In vitro: Lipid‑based transfection reagents introduce siRNA into cultured cells.
   • In vivo (systemic): Direct injection of dsRNA into the hemocoel of susceptible insects (e.g., Tribolium) induces silencing throughout the organism.
4. Validation – Quantify knock‑down by qPCR or western blot; phenotypic assessment follows.

• Loss‑of‑function studies: RNAi provides a rapid alternative to generating genetic mutants, especially in organisms where classical genetics is cumbersome.
• Functional genomics screens: Genome‑wide siRNA libraries enable high‑throughput identification of genes involved in disease pathways.
• Therapeutic potential: siRNA‑based drugs have entered clinical trials for conditions such as hereditary transthyretin amyloidosis, exploiting the pathway’s ability to silence disease‑causing transcripts.

• Off‑target effects: Partial complementarity can lead to unintended silencing of non‑target genes.
• Variable efficiency: Not all cell types uptake siRNA equally; systemic RNAi is absent in many mammals, requiring delivery vectors (lipid nanoparticles, viral vectors).
• Transient nature: siRNA-mediated knock‑down typically lasts days to weeks; for stable silencing, short hairpin RNA (shRNA) constructs integrated into the genome are preferred.

Pharmacogenetic testing determines a patient’s genotype for drug‑metabolising enzymes and translates this information into a predicted metabolic phenotype.
The most frequently examined cytochrome P450 genes in clinical practice are CYP2D6, CYP1A2, CYP2C19 and CYP2B6.

• CYP2D6 – Because the gene is highly polymorphic, a single test may reveal a normal, reduced, or absent enzyme activity. The result guides dose adjustment for drugs such as codeine, tramadol and many antidepressants.
• CYP1A2 – Genotyping is especially useful in smokers, as tobacco strongly induces this enzyme. Knowing the variant helps anticipate altered clearance of drugs like theophylline and clozapine when a patient stops smoking during hospitalisation. ^[1]
• CYP2C19 – Approximately half of individuals carry a variant that either increases or decreases activity, influencing the effectiveness of clopidogrel and selective serotonin reuptake inhibitors (SSRIs). ^[1]
• CYP2B6 – This enzyme also contributes to the metabolism of certain SSRIs and is considered when CYP2C19 activity is abnormal.

The laboratory workflow typically involves:

1. DNA extraction from peripheral blood or buccal swab.
2. Targeted amplification of the relevant exons using polymerase‑chain reaction (PCR).
3. Allele‑specific detection by real‑time PCR, microarray, or next‑generation sequencing (NGS).
4. Interpretation according to consensus guidelines (e.g., CPIC) to assign a phenotype (poor, intermediate, normal, ultra‑rapid).

Because CYP2D6 has two nearby pseudogenes (CYP2D7, CYP2D8), assays must be designed to avoid co‑amplification, a recognised technical challenge that drives ongoing method refinement. ^[1]

• Incomplete variant coverage – Newly described alleles may not be included in commercial panels, leading to misclassification.
• Population bias – Allele frequencies differ between ethnic groups; a test validated in one population may not be accurate in another.
• Phenotype translation gaps – Laboratories may use different algorithms to convert genotype to activity score, creating inconsistent reports.
• Induction vs. genotype – For CYP1A2, smoking status can mask the effect of a genetic variant; failure to record tobacco use may result in erroneous dosing decisions.
• Sample quality – Degraded DNA yields poor amplification, especially for long amplicons required to span complex CYP loci.

Pharmacogenetic panels are now embedded in several clinical pathways:

• Cardiology – CYP2C19 testing before prescribing clopidogrel after percutaneous coronary intervention.
• Psychiatry – CYP2D6 and CYP2B6 genotyping to personalise antidepressant and antipsychotic dosing.
• Oncology – Tailoring tamoxifen therapy based on CYP2D6 activity.
• Primary care – Pre‑emptive panels ordered for patients with polypharmacy, especially when drugs with narrow therapeutic windows are anticipated.

The decision‑making process can be visualised in the flowchart below.